
Pfizer lifted its revenue and adjusted-profit outlook after quarterly sales and adjusted earnings exceeded analyst expectations.
Pfizer raised its full-year revenue and adjusted-profit forecasts after third-quarter results beat analyst estimates. The company cited strong year-to-date performance and ongoing cost cuts.
The drugmaker now expects revenue of $62 billion to $64 billion, up from its prior range of $60.5 billion to $62.5 billion. Its adjusted profit forecast is $2.95 to $3.05 per share, compared with $2.80 to $3 previously.
Third-quarter adjusted earnings came in at 87 cents per share, above the 73 cents analysts expected, based on an LSEG survey. Revenue was $16.58 billion, topping the $15.87 billion estimate and roughly flat from a year earlier.
Sales of Eliquis rose 25% to $2.52 billion. Pfizer’s COVID-19 vaccine brought in $808 million, while Paxlovid sales were $449 million; both products beat analyst expectations.
Net income fell to $3.24 billion, or 56 cents per share, from $3.54 billion, or 62 cents per share, in the same quarter of 2025. Pfizer also named Cecile Guegan chief financial officer this month. She had served as interim CFO since August.
Pfizer is targeting about $9.7 billion in net savings through 2029 under its expanded cost-cutting plan.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.